Imunon’s (IMNN) “Buy” Rating Reiterated at D. Boral Capital

Imunon (NASDAQ:IMNN)‘s stock had its “buy” rating restated by research analysts at D. Boral Capital in a research note issued on Thursday,Benzinga reports. They presently have a $29.00 target price on the stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of Imunon in a research note on Thursday, December 19th.

Imunon Stock Up 0.2 %

NASDAQ IMNN traded up $0.00 during trading hours on Thursday, hitting $0.81. The company had a trading volume of 184,772 shares, compared to its average volume of 163,790. Imunon has a fifty-two week low of $0.64 and a fifty-two week high of $3.65. The business has a fifty day simple moving average of $0.89 and a 200-day simple moving average of $0.95. The firm has a market cap of $11.69 million, a P/E ratio of -0.43 and a beta of 2.03.

Imunon (NASDAQ:IMNN) last issued its earnings results on Thursday, February 27th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.13. Equities analysts forecast that Imunon will post -1.68 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Imunon stock. Geode Capital Management LLC boosted its position in shares of Imunon, Inc. (NASDAQ:IMNN) by 10.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 139,505 shares of the company’s stock after buying an additional 13,570 shares during the quarter. Geode Capital Management LLC owned 0.96% of Imunon worth $133,000 at the end of the most recent quarter. Institutional investors own 4.47% of the company’s stock.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.